Neo Ivy Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Neo Ivy Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-73,601	Closed	-$1.54M	–	472
2026 Q1	$1.54M	Buy	+73,601	New	+$1.66M	0.41%	96
2022 Q4	$141K	Buy	+3,054	New	+$120K	0.1%	245
2021 Q4	–	Sell	-3,864	Closed	-$302K	–	597
2021 Q3	$302K	Buy	+3,864	New	+$349K	0.35%	104
2020 Q3	–	Sell	-3,864	Closed	-$302K	–	591
2020 Q2	$302K	Buy	+3,864	New	+$256K	0.35%	104

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Neo Ivy Capital Management's RARE Position: Q2 2026 in Review

Neo Ivy Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 73,601 shares — an estimated $1.54M sold.

Neo Ivy Capital Management first reported a position in RARE in Q2 2020 and held it in 4 quarters. The position peaked at $1.54M in Q1 2026. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Neo Ivy Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Neo Ivy Capital Management sold 73,601 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.54M.
Neo Ivy Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and held it in 4 quarters.
Neo Ivy Capital Management's Ultragenyx Pharmaceutical position peaked at $1.54M in Q1 2026.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.